Join
Live feed
·
PRReleasevia Quantisnow
TScan Therapeutics Inc. logo

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

ByQuantisnow·Wall Street's wire, on your screen.
TCRX· TScan Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TCRX (TScan Therapeutics Inc.) and more on Quantisnow.